Sign up
Log in
Spero Therapeutics says FDA approves Utebzi oral antibiotic for adults with complicated UTIs
Share
Listen to the news
Spero Therapeutics says FDA approves Utebzi oral antibiotic for adults with complicated UTIs
  • FDA cleared Utebzi (tebipenem pivoxil) to treat adults with complicated UTIs, including pyelonephritis, when oral options are limited.
  • First oral carbapenem antibiotic approved in the US; GSK holds exclusive global rights under its licensing deal with Spero Therapeutics.
  • Approval backed by Phase III PIVOT-PO data showing non-inferiority versus IV imipenem-cilastatin; US launch expected by end-2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief on June 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
Terms of Service·Privacy Policy·Data Disclaimer
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved